Dementia of the Alzheimer’s type with delusions brings unique challenges that go beyond memory loss. When a person develops false beliefs or becomes suspicious without reason, it affects their sense of safety and their relationships with loved ones. Understanding treatment approaches—both established therapies and those being explored in research—helps families and caregivers navigate this difficult journey with more confidence and support.

Understanding Treatment Goals and Options

When dementia progresses to include delusions—false beliefs that feel completely real to the person experiencing them—the focus of treatment shifts toward reducing distress, improving safety, and preserving quality of life for both the person with dementia and their family. Treatment does not aim to cure the underlying dementia, but rather to manage these challenging behavioral symptoms that can emerge as the disease affects different parts of the brain.^[1]

People with Alzheimer’s disease may develop a specific type of delusion called paranoia, where they believe—without any real reason—that others are lying, stealing from them, or trying to harm them. This often connects to memory loss: when someone forgets where they placed an item, they may conclude that someone took it. When they forget that a caregiver is there to help, that person may seem like a threatening stranger.^[3]

Treatment depends heavily on the stage of disease and how much these symptoms interfere with daily life. Not every delusion requires medication—some are mild and fleeting. The decision to intervene typically considers whether the delusions cause significant fear, lead to dangerous behavior, or create unbearable stress for caregivers. Medical societies recommend starting with approaches that don’t involve medication whenever possible, and using drugs only when other strategies haven’t helped enough.^[11]

Research continues into new medications and approaches specifically designed to address these behavioral and psychological symptoms. Clinical trials are testing drugs that might reduce delusions while causing fewer side effects than older medications. Some of these investigational treatments work on brain chemistry in novel ways, offering hope that future options may be safer and more effective.^[15]

Standard Treatment Approaches

Before considering any medication, doctors typically recommend what are called non-pharmacologic interventions—strategies that don’t involve drugs. These form the foundation of managing delusions and paranoia in Alzheimer’s disease. The approach begins with a thorough medical evaluation, because sometimes delusions are triggered or worsened by other health problems. Infections like urinary tract infections, dehydration, constipation, pain, or reactions to medications can all contribute to confused thinking and paranoid beliefs.^[4]

Caregivers learn specific techniques for responding when their loved one expresses a delusional belief. Rather than arguing about what’s real—which usually doesn’t work and can increase agitation—the recommended approach involves acknowledging the person’s feelings, offering reassurance, and gently redirecting attention to something else. For example, if someone believes their belongings are being stolen, a caregiver might respond with empathy (“I can see you’re worried about your things”) and then suggest moving to another room or looking at family photos together.^[10]

Environmental modifications can reduce triggers for paranoia and delusions. This includes ensuring good lighting to prevent shadows that might be misinterpreted, reducing background noise from television or radio that can be confusing, checking that the person wears glasses or hearing aids if needed, and maintaining familiar routines. Violent or disturbing television programs should be turned off, as someone with dementia may believe the events are actually happening in their home.^[3]

When behavioral approaches aren’t sufficient, medication may be considered. However, the choice of which drug to use, at what dose, and for how long requires careful medical judgment. The approach often described as “start low, go slow” means beginning with the smallest possible dose and increasing gradually only if needed, while watching closely for both benefits and side effects.^[13]

Atypical antipsychotic medications are currently the most commonly prescribed drugs for delusions in Alzheimer’s disease. These include risperidone and haloperidol. Risperidone is the only medication licensed specifically for treating persistent aggression or extreme distress in people with moderate to severe Alzheimer’s disease when there is risk of harm. It should be used at the lowest effective dose and for the shortest time possible, with regular reviews at least every six weeks. Haloperidol may be used when other treatments haven’t worked.^[17]

These medications work by affecting chemical messengers in the brain, particularly dopamine, which is involved in perception and thought processes. While they can reduce the intensity and frequency of delusions, they come with significant warnings. In older adults with dementia-related psychosis, antipsychotic drugs carry an increased risk of death, which is why they must be prescribed and monitored by specialists, typically consultant psychiatrists who have expertise in dementia care.^[16]

Side effects of antipsychotic medications can include increased sedation, dizziness, higher risk of falls, movement problems resembling Parkinson’s disease, and metabolic changes. Because of these concerns, guidelines emphasize that non-drug approaches should always be tried first, and medication should be reserved for situations where delusions cause severe distress or danger that cannot be managed through other means.^[14]

Cholinesterase inhibitors—medications originally developed to help with memory and thinking—have also been studied for their effects on behavioral symptoms like delusions. These include donepezil, rivastigmine, and galantamine. They work by preventing the breakdown of acetylcholine, a brain chemical important for nerve cell communication. While primarily prescribed to address cognitive decline, some evidence suggests these medications may have modest benefits for reducing delusions and other behavioral symptoms in Alzheimer’s disease.^[14]

Another medication called memantine works differently—it blocks excessive activity of a brain chemical called glutamate. This drug is approved for moderate to severe Alzheimer’s disease and may help with behavior problems, though its primary purpose is addressing memory and thinking difficulties rather than specifically treating delusions.^[17]

Sometimes doctors prescribe antidepressants if they suspect that underlying anxiety or depression is contributing to paranoid thinking. Medications from the SSRI class (selective serotonin reuptake inhibitors) may help reduce anxiety that fuels suspicious thoughts. However, these are considered supportive treatments rather than primary interventions for delusions themselves.^[11]

Second-line treatment options that may be considered include anticonvulsant medications like divalproex or carbamazepine. These were originally developed to prevent seizures but have been studied for managing agitation and behavioral disturbances in dementia. They are typically tried when antipsychotics haven’t been effective or can’t be tolerated due to side effects.^[13]

The duration of treatment varies by individual. Some people may need medication for only a short period during a particularly difficult phase, while others may require longer-term treatment. Guidelines recommend regular reassessment—every few weeks or months—to determine whether the medication is still needed and beneficial, or whether the dose can be reduced or the drug discontinued. The goal is always to use the minimum intervention necessary to maintain safety and quality of life.^[17]

Treatment Being Tested in Clinical Trials

Researchers recognize that current treatment options for delusions in Alzheimer’s disease are limited and come with significant drawbacks. This has sparked intensive investigation into new medications that might work better with fewer side effects. Several promising approaches are being tested in clinical trials, offering hope for improved care in the future.

One of the most advanced investigational treatments is pimavanserin, a medication that was originally approved by the FDA in 2016 for treating psychosis in Parkinson’s disease. Unlike traditional antipsychotics that primarily affect dopamine receptors, pimavanserin works through a different mechanism—it selectively targets serotonin receptors in the brain, specifically the 5-HT2A receptor. This different approach may reduce delusions and hallucinations while avoiding some of the serious side effects associated with older antipsychotic drugs.^[15]

In a significant clinical trial, researchers tested pimavanserin in nearly 400 people with different types of dementia, including Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, and Parkinson’s disease dementia. The study design was carefully constructed: first, all participants received pimavanserin to identify those who responded well. Then, the responders were randomly divided into two groups—half continued taking pimavanserin while the other half switched to placebo pills. This design helps researchers understand whether the drug truly prevents symptoms from returning.^[15]

According to experts quoted in research reports, about 30 to 40 percent of people with Alzheimer’s disease experience hallucinations and delusions at some point during their illness. These symptoms pose great challenges for patients and families, sometimes becoming severe enough that home care is no longer possible. The potential approval of pimavanserin for Alzheimer’s disease psychosis could provide the first FDA-approved treatment specifically for these symptoms, which would represent a significant milestone.^[16]

The drug is taken as a once-daily pill. In clinical trials, researchers measured its effects on reducing the frequency and intensity of delusions and hallucinations, as well as its impact on quality of life for both patients and caregivers. Safety monitoring included watching for side effects and comparing rates of serious complications between those taking the drug and those receiving placebo. While the medication showed promise in earlier trials, it’s important to note that the manufacturer includes warnings about potential risks, and any new approval would come with careful guidance about appropriate use.^[16]

The clinical trials examining pimavanserin for Alzheimer’s disease psychosis have progressed through multiple phases. Phase I trials focus on safety, determining what doses humans can tolerate and how the body processes the drug. Phase II trials examine whether the drug actually works—does it reduce symptoms at various doses? Phase III trials compare the new treatment against current standard care (or placebo) in larger groups of patients, providing the strongest evidence about effectiveness and safety before regulatory approval can be sought.^[15]

Research has been conducted in multiple countries including the United States. Patients enrolled in these trials typically needed to have a confirmed diagnosis of dementia along with significant delusions or hallucinations that caused distress or behavioral problems. They often could not be taking other antipsychotic medications during the study, to avoid confusing the results. Caregivers played an important role in the trials, reporting on symptoms and behavioral changes throughout the study period.^[15]

Beyond pimavanserin, researchers are investigating other innovative approaches to treating behavioral symptoms in Alzheimer’s disease. Some studies are examining whether existing cholinesterase inhibitors like rivastigmine might be more effective for delusions than previously recognized, particularly in patients who also have visual hallucinations. The theory is that by boosting acetylcholine—a brain chemical involved in attention and perception—these drugs might help the brain more accurately process reality.^[14]

Scientists are also studying the brain mechanisms underlying delusions in dementia. Advanced brain imaging techniques and studies of brain tissue have revealed that delusional symptoms may result from damage to specific brain regions involved in memory, visual processing, and emotional regulation. This understanding could lead to more targeted treatments in the future—drugs or other interventions designed to support the specific brain functions that become impaired, rather than just suppressing symptoms broadly.^[4]

Some research explores whether certain populations might respond differently to treatments. For example, studies have noted that the frequency and nature of delusions can vary across different forms of dementia—they are more common in dementia with Lewy bodies (occurring in about 75 percent of patients) than in Alzheimer’s disease (affecting roughly one-third of patients). This suggests that different underlying brain changes may require tailored treatment approaches.^[26]

Preliminary results from trials of newer medications have shown some encouraging signs. In studies where pimavanserin was compared to placebo, researchers found that patients taking the active drug experienced fewer relapses of psychotic symptoms and showed improvement on standardized scales measuring delusions and hallucinations. However, experts emphasize that while these results are promising, more research is needed to fully understand the long-term effects and optimal use of such treatments.^[15]

The safety profile of investigational drugs is carefully monitored throughout clinical trials. For pimavanserin, initial safety reviews by regulatory authorities found no new or unexpected safety risks beyond those already known from its use in Parkinson’s disease psychosis. However, the medication still carries important warnings, including the general caution about increased death risk with antipsychotic-type drugs in elderly dementia patients. Researchers continue to study whether the different mechanism of action might translate into a better overall benefit-risk balance compared to older medications.^[15]

Looking further ahead, scientists are investigating completely different treatment strategies. Some research examines non-drug interventions like specialized forms of psychotherapy adapted for dementia, music therapy, sensory stimulation programs, and technological aids that might reduce confusion and paranoid thinking. While these approaches are still experimental for treating delusions specifically, they represent the broader principle that multiple types of interventions may eventually work together to improve outcomes.^[11]

Most Common Treatment Methods

• Non-Pharmacologic Approaches
  • Environmental modifications including improved lighting, noise reduction, and maintaining familiar routines to reduce triggers for paranoid thinking
  • Communication techniques where caregivers acknowledge feelings without arguing about delusional beliefs, then redirect attention
  • Medical evaluation to identify and treat underlying causes like infections, dehydration, or medication side effects
  • Safety measures to protect both the person with dementia and others from potential harm
  • Caregiver education about the non-intentional nature of symptoms and coping strategies
• Atypical Antipsychotic Medications
  • Risperidone, used at lowest effective dose for shortest necessary time, specifically licensed for moderate to severe Alzheimer’s with risk of harm
  • Haloperidol, considered when other treatments have not been successful
  • Regular monitoring (at least every six weeks) to assess ongoing need and watch for side effects
  • Prescribed by specialists experienced in dementia care due to serious risks including increased mortality
• Cholinesterase Inhibitors
  • Donepezil, rivastigmine, and galantamine, which work by increasing acetylcholine levels in the brain
  • Primarily prescribed for cognitive symptoms but may provide modest benefit for behavioral symptoms including delusions
  • Rivastigmine may be preferred when hallucinations are prominent symptoms
• Other Medications
  • Memantine for moderate to severe Alzheimer’s disease, which blocks excessive glutamate activity
  • Antidepressants (particularly SSRIs) when anxiety or depression contribute to paranoid thinking
  • Anticonvulsants like divalproex or carbamazepine as second-line options when antipsychotics aren’t effective or tolerated
• Investigational Treatments in Clinical Trials
  • Pimavanserin, which works through selective serotonin receptor targeting rather than dopamine blockade
  • Tested in multiple dementia types including Alzheimer’s disease, vascular dementia, and Lewy body dementia
  • Currently in advanced clinical trial phases examining effectiveness and safety compared to placebo
  • If approved, would represent first FDA-approved treatment specifically for Alzheimer’s disease psychosis